Loading
Iodinated Contrast Agent / Digital Tomosynthesis Mammography / Breast Carcinoma · Interventional Study
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry record for a planned interventional study of contrast-enhanced spectral mammography (CESM) in patients with pathologic nipple discharge. No results are reported in this registry entry; the study is active but not currently recruiting, with an intended enrollment of 40 participants and a primary outcome of CESM sensitivity to be assessed over approximately one year.
Interventional, Single Group, Open label, Diagnostic purpose. Breast Carcinoma; Female; age from 25 Years; to 85 Years. Intervention: Diagnostic (CESM, DBT). n = 40. 1 site: United States.
This is a clinical trial registry record for a planned interventional study of contrast-enhanced spectral mammography (CESM) in patients with pathologic nipple discharge. No results are reported in this registry entry; the study is active but not currently recruiting, with an intended enrollment of 40 participants and a primary outcome of CESM sensitivity to be assessed over approximately one year.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No clinical impact can be assessed from this registry record, as no outcome data are reported. Results from this trial, when published, may help establish the sensitivity of CESM as a diagnostic tool for pathologic nipple discharge and its potential to reduce unnecessary biopsies.
This is a clinical trial registry record with no reported results; the study is active but not recruiting, with planned enrollment of 40 participants and a primary outcome of CESM sensitivity that has not yet been published.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record, as no outcome data are reported. Results from this trial, when published, may help establish the sensitivity of CESM as a diagnostic tool for pathologic nipple discharge and its potential to reduce unnecessary biopsies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05056844). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Breast Carcinoma. Interventions: PROCEDURE: Contrast Enhanced Digital Mammography; PROCEDURE: Digital Tomosynthesis Mammography; DRUG: Iodinated Contrast Agent; OTHER: Questionnaire Administration. Primary outcome measures: Sensitivity of contrast enhancement of contrast enhanced spectral mammography (CESM) , through study completion, an average of 1 year. Brief summary: This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. The goal of this trial is to learn if CESM, is better than standard mammography in quickly and efficiently determining the cause of nipple discharge and detecting breast cancer, if present. CESM may increase the chance of finding breast cancers and lower the risk of having unnecessary biopsies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.